HOME
ABOUT IASO
Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Publictaions
Technology Platforms
Pipeline
Manufacturing
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Growth & Development
Working at IASO
Opportunities
CONTACT
中文简体
中文繁体
English
NEWS
Press Release
Media Report
Search
05/04
2024
IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis
29/03
2024
IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma
29/02
2024
IASO Bio’s Equecabtagene Autoleucel for Refractory Myasthenia Gravis (MG) Case Report Published in EMBO Molecular Medicine
01
2024-02
Promising Clinical Results on the World’s First Use of BCMA CAR-T to Treat Immune Mediated Necrotizing Myopathy (IMNM) Published on the Proceedings of the National Academy of Sciences (PNAS)
04
2024-01
IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies
12
2023-12
IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023
28
2023-09
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
10
2023-07
IASO Bio and Innovent Announce the NMPA Approval of the NDA for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of RRMM
10
2023-07
IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease
01
2023-07
IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel(BCMA CAR-T Cell Therapy)for Multiple Myeloma at the 2023 ASCO Annual Meeting
<
1
2
3
4
5
>